Therapeutic evaluation of Unani formulation as an adjuvant in the treatment of Albuminaria in diabetic nephropathy

Diabetes mellitus is one of the most common non communicable diseases and remains today a worldwide and increasing health problem. A recent international study reported that nephropathy is the most common complication of diabetes mellitus accounting for 21.1% renal issues. Diabetic nephropathy is a long term chronic progressive microvascular complication of diabetes mellitus. It has been clinically defined by the presence of protein in urine more than or equals to 300 mg/ 24 hr in diabetic patients with the absence of other renal diseases. In classical unani literature, Buqrat (Hippocrates 460 BC) mentioned a disease with excessive urinary flow and wasting of body. Jalinoos (Galen 131-201 AD) defined diabetes as “Diarrhea Urinosa” (diarrhoea ofurine) and “dipsakos” (thirsty disease). He described it as a disease specific to kidneys because of weakness in their retentive ability. The present study entitled as “evaluation of efficacy of unani formulation as adjuvant in the treatment of diabetic nephropathy” has been carried out at Majeedia unani hospital Jamia Hamdard New Delhi from 2016-2017. A compound formulation mentioned in zakheera khawarrzam shahi containing Samaghe Arabi (acacia arabica), Gulnaar (punica granatum) Dam-al-akhwain pterocarpus marsupium), shibbe yamani (hydrated form of potassium aluminium sulphate), Badaam (prunus amygdalus) and gond kateera (sterculia urens) has been mentioned for the treatment of bole zulali in diabetes. The study reveals that the test drug has good response in treatment of albuminaria in diabetic nephropathy, as compared to control drug.